Skip to main content Accessibility help
×
Hostname: page-component-7b7567c8c-wxvwp Total loading time: 0 Render date: 2026-11-16T20:52:55.326Z Has data issue: false hasContentIssue false

4 - Cytolethal distending toxins: A paradigm for bacterial cyclostatins

Published online by Cambridge University Press:  15 September 2009

Bernard Ducommun
Affiliation:
LBCMCP-CNRS UMR5088, Université Paul Sabatier, Institut d'Exploration Fonctionnelle des Génomes (IFR109)
Jean De Rycke
Affiliation:
UR 918 INRA de Pathologie Infectieuse et Immunologie
Alistair J. Lax
Affiliation:
King's College London
Get access

Summary

During the last 10 years, information has accumulated showing that pathogenic bacteria can produce various proteins able to block the eukaryotic cell cycle or delay its progression. These observations raise the attractive hypothesis that control of cell proliferation is a real strategy of pathogenicity, giving an evolutionary advantage to bacteria, and not simply a fortuitous effect observable in cell cultures, the interest of which would eventually be confined to cellular biologists or pharmacologists. The ultimate objective of this chapter is to analyse critically the pertinence of this candidate concept within the field of cellular microbiology (Cossart et al., 1996; Henderson et al., 1998) and to propose tentative criteria to define what we suggest calling bacterial cyclostatins.

We have chosen cytolethal distending toxin (CDT) as a prototype cyclostatin. From a probable common ancestor, CDT has spread through the bacterial world and it can be found in several Gram-negative pathogenic bacteria, constituting a family of toxins sharing common molecular and biological properties in spite of a large genetic dispersion (De Rycke and Oswald, 2001). The presence of a CDT homologue in various unrelated bacterial species is peculiar and suggests that CDT confers a strong selective advantage to producing bacteria, possibly helping adaptation to the host and ecological niche, or increasing pathogenicity. Another major interest in using CDT as a prototype cyclostatin is that a consistent picture of its mode of action on mammalian cells is now emerging, as a result of intensive research effort in recent years by several teams of investigators.

Information

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×